IntroductIon
The purpose of this review is to discuss the various means by which iodine ingestion through dietary intake or therapeutic administration can influence the pathogenesis, prevalence, presentation or outcome of differentiated thyroid cancer (DTC). The relationship between iodine nutrition and DTC pathogenesis is complex, arising from the fundamental observation that anything that stimulates thyroid growth such as TSH, has the potential ability to promote growth and neoplastic transformation in predisposed thyroid follicular cells. [1] [2] [3] One of the other major factors in the pathogenesis of thyroid cancer is previous irradiation. 16 The mechanisms through which events leading to PTC are initiated is uncertain but RET/PTC rearrangements as well as RAS, PAX 8 and PPAR  mutations have been implicated. 17, 19 The sources of irradiation implicated in causing PTC have included the consequences of the nuclear accident at Chernobyl where exposure to radioactive iodine may have been aggravated by the low dietary iodine intake in the affected population.
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Iodine Intake
Since both low and high dietary iodine intake can result in increased serum TSH, variations in dietary iodine intake can in susceptible individuals be carcinogenic. Examination of these factors has led to a diversity of findings in terms of thyroid cancer prevalence with higher rates being reported in areas of both low and high dietary iodine intake. 2, [4] [5] [6] [7] [8] There are many factors, such as ethnicity, selenium and goitrogen or carcinogen intake that complicate studies linking changes in DTC rates to iodine intake. 3 Although there continues to be disagreement on whether iodine intake determines the absolute prevalence of DTC, there is strong evidence that such intake influences its form of presentation with follicular thyroid carcinoma predominating in areas of dietary iodine deficiency while the papillary form is most common where iodine intake is replete or excessive 5, 9 (Table 1) . Furthermore, a shift towards the papillary form occurs when a population has undergone a programme of iodine prophylaxis. 2, [10] [11] [12] Although the relative proportion of both follicular and anaplastic thyroid cancer declines with increas-ing iodine intake, there are conflicting views as to whether iodine deficiency results in an increased incidence of the more aggressive histological subtypes. 2, 12, 13 However, it should be noted that despite increased prevalence, the mortality rate for thyroid cancer has remained relatively constant, suggesting that the increases observed may reflect the use of improved diagnostic procedures revealing hitherto undetected PTC of <1.0cm. 2, 14 Studies from Tasmania, while confirming the dominant finding of a higher prevalence of small (<1.0cm) thyroid cancers in an iodine deficient population, also demonstrated an increase in prevalence of tumours >1.0cm.
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IodIne excess
As previously stated both excess iodine intake or a shift from lower to higher intakes has been associated with increased prevalence of PTC. 5, 10, 11 However the picture regarding excess iodine and possible PTC induction is far from clear. In addition to its effect on thyroid function through the induction of hypothyroidism (the Wolff-Chaikhoff effect), a protective effect against the proliferation of thyroid and other cells has been attributed to excess iodine. [21] [22] [23] Iodine may exert its effect by inhibiting cAMP formation in response to stimuli perhaps through autoregulation by iodolipids such as iodolactones. 24, 25 Excess iodine cytotoxicity appears to reside in molecular iodine (I2) rather than iodide (I   -) 26 since PTU, an inhibitor of TPO and therefore of iodide organification, completely blocked iodide cytotoxicity. This mechanism appeared to involve apoptosis and may reside in the antioxidative effect of I2 27, 28 as Vitamin E deficiency, resulting in reduced antioxidative protection, significantly increases cell death.
radIoactIve IodIne
Whatever the merits of the cytotoxic properties of stable iodine, there is no question that radioactive 131 I has the ability to ablate thyroid tissue. However, there is considerable debate on the therapeutic benefits of such therapy in ablating gland remnant at least in so called "low risk" PTC. 29 Nevertheless, to achieve the desired ablative effect in thyroid carcinoma, it is necessary that the tumour or metastatic tissue have the ability both to accumulate radioiodide and to retain it within cells for a sufficient period. These various objectives are achieved providing that a number of preconditions as stated below can be satisfied. [30] [31] [32] [33] 1. The circulating concentration of stable iodine must be low enough to permit entry of 131 I into cells so that competition for entry will not prevent accumulation of radioactivity in thyroid cells. In some cases this may require a low iodine diet for two weeks before administration of 131 I.
2. The transmembrane I -transporter NIS must be 3. NIS must not only be present but must be targeted to the appropriate basolateral cell membrane of the thyroid follicular cell.
4. Mechanisms to achieve retention of 131 I, such as the enzyme thyroid peroxidase which participates in the organification of I-must be active within the thyroid cell.
restorIng nIs FunctIon
Many cases of cancer of the thyroid gland remnants or functioning metastases have either diminished or neglible ability to concentrate 131 I. Such 131 I refractoriness is often proportional to the degree of tumour dedifferentiation. 33, 34 Various means have been employed to promote NIS upregulation and therefore 131 I uptake. These include attempts to induce endogenous NIS expression by means of cell redifferentiation or use of transgenic therapy whereby the NIS is reintroduced into cells. 31 Most of the work on upregulation of NIS has been conducted on thyroid cell lines using a variety of agents such as retinoic acid or troglitazone (a PPAR- analogue) 35, 36 which also inhibits cell proliferation. Other agents aim at reversing epigenetic changes in NIS DNA. These include demethylating agents such as 5-azacytidene, sodium butyrate 37 or histone deacetylase inhibitors such as trichostatin A, depsipeptide or valproic acid. 38, 39 Some representative aspects of attempts made in our laboratory to increase radioactive iodide, in this case 125 I, uptake in a thyroid follicular cancer cell line (FTC133) are depicted in Figure 1 . 40 This figure shows the effect on 125 I uptake of incubating FTC133 cells with increasing concentrations of the histone deacetylase inhibitor trichostatin -A (TSA) over 4 hours. It can be seen that small increases in uptake (Max 40%) were observed, achieving significance at a TSA concentration of 12.5ng/ml but declining thereafter.
IodIne In seaweeds
The element Iodine was first discovered in seaweed by the French scientist Bernard Courtois (1811) when he treated seaweed ash with sulfuric acid. The iodine of seaweeds varies greatly between different seaweed species and, despite many years of investigation, the function of iodine and mechanism of iodide uptake in seaweeds is still unknown. What is known is the ability of seaweeds to take up iodine from seawater against a concentration gradient and, depending on the species concentrate it up to 60,000 times the concentration of this element in seawater 41 ( Table 2) . The mechanism by which these organisms accumulate iodine is not fully understood, however, although it has been suggested that in members of the Laminaria family of seaweeds, uptake involves extracellular haloperoxidase-mediated oxidation of iodide to molecular iodine. 42 The analogy between the thyroid and seaweed is based on the fact that that the relationship of the thyroid to the bloodstream is similar to that of seaweed to seawater. 43 In addition to its ability to accumulate iodide by a significantly greater factor than the human thyroid, many seaweeds can retain iodide within the plant despite the presence of a large concentration gradient between the iodine rich plant (mg/kg) and the relatively iodine poor seawater (~60μg/L). In our study we have elaborated on the following aspects:
1. Uptake and efflux of radioactive 125 I by different seaweeds.
2. Chemical form in which iodine is stored within seaweeds.
3. Mechanism by which 125 I is taken up and stored within seaweeds. shown in Figure 3 . It can be seen that there was relatively little efflux (<10%) up to 420 mins with significant loss only being observed after overnight incubation (1440 mins) which is probably the result of tissue necrosis. The level of efflux observed contrasted with that seen in a rat FRTL-5 thyroid cell line, where 85 % and 95% of accumulated 125 I was lost at 30 and 60 mins, respectively.
general coMMents
Despite the absence of conclusive evidence that dietary iodine intake influences the incidence of thyroid cancer, many reports from different regions show an increasing incidence of the disease. 1, 20 Although much of this reported increase can no doubt be attributed to improved detection of small (<1.0cm) tumours, a role for iodine intake cannot be totally excluded. 2, 20 The antiproliferative effects of excess iodine on thyroid cells in vitro has been reported, 22, 23 although the possible therapeutic relevance of such 4. Can understanding these mechanisms assist in improving the effectiveness of radioactive iodine ablative therapy for cancer? uPtake oF 125 I Figure 2 shows the effect of incubating a variety of seaweed species for varying periods of time with 125 I and measuring uptake in plant tissues. The ability to accumulate 125 I varied with maximum uptake observed in Chondrus Crispus (Carrageen Moss) and Laminaria Digitata (Kombu). The uptake could be inhibited in a concentration dependent manner by sodium perchlorate, (1.0uM -1.0mM) suggesting competition for iodide transport analogous to that seen in the human thyroid. Unlike stable iodine, the cytotoxic effect of radioactive ablative therapy is well established. However, thyroid cancer cells when dedifferentiated often lose the ability to concentrate iodide and become refractive to radioiodine treatment. Inability to concentrate radioiodide often reflects the loss of NIS or of NIS targeting to the appropriate basolateral membrane of the thyroid follicular cell. Attempts to improve the ability of the thyroid to accumulate radioiodide have involved so called redifferentiation therapy using retinoic acid, upregulation of NIS with troglitazone (PPAR agonist) or agents aimed at reversing epigenetic modifications of NIS DNA, such as demethylation by 5-azacytidine, [35] [36] [37] [38] [39] the histone acetylase inhibitors trichostatin, depsipeptide or valproic acid. Despite extensive studies, these approaches have only shown a modest effect, as was the case in the use of the histone acetylase inhibitor trichostatin shown in this report. Enabling cells to accumulate radioiodide is not in itself sufficient to achieve ablation. In order to achieve a cytotoxic effect, the radioisotope has to be retained within the cell for a sufficient period to enable the radiation to destroy the surrounding tissue. Attempts to increase 131 I retention time in the thyroid have included the use of lithium salts 45, 46 to increase the effective biological t1/2 of 131 I.
The difficulty of promoting 131 I accumulation and retention by a significant proportion of thyroid cancers prompted the study of another model having properties similar to the thyroid. The model selected was seaweed which bears the same relationship to its surrounding seawater as does the thyroid to the blood circulation. Uptake of 125 I into seaweeds correlated directly with their iodine content, the higher uptakes being observed in seaweeds with the greatest iodine content. Studies on 125 I efflux from seaweeds showed that the species tested had a remarkable ability to retain 125 I even in the presence of a large concentration gradient. The iodine content of seawater is of the order of 50-60μg/l while that of seaweeds species investigated in this study is of the order of 280-5000 mg/kg. 47, 48 The ability of the seaweed L. Digitata to retain up to 80% 125 I even after 24 hrs incubation contrasted with that of the rat thyroid FRTL-5 cell line which lost 83% after 30 mins and 97% after 60mins.
conclusIons
A possible role for dietary iodine intake in influencing thyroid cancer prevalence remains to be elucidated. It is of course highly probable that superimposition of iodine deficiency or excess onto a thyroid already genetically susceptible to thyroid cancer or in whom a mutation, radiation insult or ingestion of a chemical carcinogen may provide a stimulus to carcinogenesis. While thyroid gland ablation by radioactive 131 I, the adjunct treatment of choice for gland remnant or metastatic ablation, the means of restoring 131 I concentrating ability lost during tumour dedifferentiation leave a lot to be desired. The same applies to methods of promoting 131 I retention time within thyroid cells. The ability to accumulate and retain 131 I has been studied in seaweeds. The author is well aware that ion transport systems in primitive algae may be far removed from those in the mammalian thyroid. However, the properties exhibited by seaweeds, in terms of efficient uptake of iodide and in particular retentive ability, suggest that further exploration of these properties has the potential of providing some insights which may benefit the therapeutic use of radioiodine. 
